Stockscreener 앱 받기
7.99
11.13%
0.80
전일 마감가:
$7.19
열려 있는:
$7.14
하루 거래량:
1.23M
Relative Volume:
12.12
시가총액:
$83.90M
수익:
$1.93M
순이익/손실:
$-7.96M
주가수익비율:
-0.00226
EPS:
-3530.8178
순현금흐름:
$-36.78M
1주 성능:
+15.80%
1개월 성능:
+4.31%
6개월 성능:
-2.56%
1년 성능:
+42.17%
1일 변동 폭
$7.07
$8.40
1주일 범위
$6.4758
$8.90
52주 변동 폭
$4.35
$34.46
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
540 GAITHER ROAD, ROCKVILLE
AVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
7.99 | 83.90M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
(AVTX) Investment Analysis - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Piper Sandler - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - Nasdaq
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga India
Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target -February 28, 2025 at 07:54 am EST - Marketscreener.com
Piper Sandler sets $48 target on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Wedbush to "Strong-Buy" Rating - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Wedbush - MarketBeat
Avalo Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Avalo Therapeutics (NASDAQ:AVTX) Trading Up 3.1%Time to Buy? - MarketBeat
Avalo Therapeutics initiated with an Outperform at Wedbush - MSN
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Wedbush - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wedbush - Defense World
Avalo climbs as Wedbush issues bullish view on lead asset - MSN
(AVTX) Trading Advice - Stock Traders Daily
Avalo stock climbs on Wedbush bullish view (AVTX:NASDAQ) - Seeking Alpha
Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target -February 21, 2025 at 07:51 am EST - Marketscreener.com
(AVTX) Technical Data - Stock Traders Daily
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 176.2% in January - MarketBeat
(AVTX) Investment Report - Stock Traders Daily
When (AVTX) Moves Investors should Listen - Stock Traders Daily
AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 11.8% - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Trading Up 6.5%Still a Buy? - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 6.5% – Still a Buy? - Defense World
(AVTX) Trading Signals - Stock Traders Daily
Avalo Therapeutics appoints first chief strategy officer - Pennsylvania Business Report
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - citybiz
Avalo Therapeutics Names Biogen Veteran Jennifer Riley as Chief Strategy Officer to Lead $10B Market Push - StockTitan
(AVTX) Proactive Strategies - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Increases By 340.4% - MarketBeat
BTIG Research Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Avalo Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG optimistic on Avalo Therapeutics stock with potential for transformative Phase 2b trial results - Investing.com Canada
(AVTX) Trading Report - Stock Traders Daily
LUCID CAPITAL MARKETS Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - MSN
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Drops By 46.9% - MarketBeat
Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - TipRanks
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):